A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Clinical trial NCT03516981 · COMPLETED

Trial details

NCT number: NCT03516981
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Non-Small Cell Lung Cancer

Start date: 2018-10-01
Primary completion: 2025-06-13
Enrollment: 245

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.